Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 16/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1697797 | 0.91 | PDE4A (0.71) | PDE4APDE4DPDE4BPDE3BPDE3A | |
| SCHEMBL14935972 | 0.89 | PDE4A (0.59) | PDE4APDE4DPDE4BPDE3BPDE3A | |
| SCHEMBL1697793 | 0.88 | PDE4A (0.72) | PDE4APDE4DPDE4BPDE3BPDE3A | |
| SCHEMBL1697760 | 0.87 | PDE4A (0.66) | PDE4APDE4DPDE4BPDE4CABCB11 | |
| SCHEMBL14936198 | 0.84 | PDE4A (0.83) | PDE4APDE4DPDE4BPDE3BPDE3A | |
| SCHEMBL1697743 | 0.77 | PDE4A (0.70) | PDE4APDE4DPDE4BPDE4CABCB11 | |
| SCHEMBL1697753 | 0.77 | PDE4A (0.71) | PDE4APDE4DPDE4BPDE3BPDE3A | |
| SCHEMBL1697765 | 0.76 | PDE4A (0.73) | PDE4APDE4DPDE4BPDE3BPDE3A | |
| SCHEMBL14935849 | 0.76 | PDE4A (0.61) | PDE4APDE4DPDE4BPDE4CABCB11 | |
| SCHEMBL1697786 | 0.75 | PDE4A (0.71) | PDE4APDE4DPDE4BPDE4CABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637499-B2 | Benzodioxole or benzodioxepine heterocyclic compounds as phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2017-05-02 | — | — | US | disclosed |
| US-9273064-B2 | Benzodioxole or benzodioxepine heterocyclic compounds as phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2016-03-01 | — | — | US | disclosed |
| US-20160022657-A1 | BENZODIOXOLE OR BENZODIOXEPINE HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2016-01-28 | — | — | US | disclosed |
| US-20150111915-A1 | BENZODIOXOLE OR BENZODIOXEPINE HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2015-04-23 | — | — | US | disclosed |
| US-8980905-B2 | Benzodioxole or benzodioxepine heterocyclic compounds as phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2015-03-17 | — | — | US | disclosed |
| US-20130123291-A1 | BENZODIOXOLE OR BENZODIOXEPINE HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2013-05-16 | — | — | US | disclosed |
| EP-2585469-A1 | BENZODIOXOLE OR BENZODIOXEPINE HETEROCYCLIC COMPOUNDS PHOSPHODIESTERASE INHIBITORS | Leo Pharma A/S (DK) | 2013-05-01 | — | — | EP | disclosed |
| WO-2011160632-A1 | BENZODIOXOLE OR BENZODIOXEPINE HETEROCYCLIC COMPOUNDS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2011-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111915-A1 | BENZODIOXOLE OR BENZODIOXEPINE HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | PDE3A, PDE4A, PDE2A | PDE4A 2/4885PDE4D 16/4885PDE4B 6/4885 |
| US-20160022657-A1 | BENZODIOXOLE OR BENZODIOXEPINE HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | PDE3A, PDE4A, PDE2A | PDE4A 2/4885PDE4D 16/4885PDE4B 6/4885 |
| US-20130123291-A1 | BENZODIOXOLE OR BENZODIOXEPINE HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | PDE3A, PDE4A, PDE2A | PDE4A 2/4885PDE4D 18/4885PDE4B 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.